To include your compound in the COVID-19 Resource Center, submit it here.

BeiGene starts Phase III of BGB-3111 in untreated CLL and SLL

BeiGene Ltd. (NASDAQ:BGNE) started a Phase III trial to evaluate twice-daily 80

Read the full 121 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE